Mercer Global Advisors
MAZE

Mercer Global Advisors’s Maze Therapeutics MAZE Stock Holding History

Mercer Global Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Buy
+574
New +$15K ﹤0.01% 4905

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Mercer Global Advisors's MAZE Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 574 shares worth $17.1K. The stake represents ﹤0.01% of the portfolio and ranks #4905 among its holdings.

114 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Mercer Global Advisors held 574 shares of Maze Therapeutics worth $17.1K as of Q2 2026.
  • Maze Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Maze Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4905 holding.
  • 114 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.